Nurix raises $120M in week’s second major protein degradation financing

Nurix to deploy venture funds to advance multiple preclinical programs into the clinic in next two years

Nurix’s $120 million funding round is the second fund-raising for a targeted protein degradation company in excess of $100 million this week. Along with Kymera’s $102 million round, Nurix’s deal reflects the promise investors see in the emerging modality, even amid the COVID-19 crisis.

Nurix Therapeutics Inc. said it will advance several of its lead preclinical programs into the clinic over the

Read the full 611 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers